Other analysts have also issued research reports about the company. Zacks Investment Research upgraded Shire PLC from a hold rating to a buy rating and set a $192.00 price objective for the company in a report on Wednesday, June 29th. Goldman Sachs Group Inc. restated a buy rating on shares of Shire PLC in a report on Tuesday, June 28th. Leerink Swann reaffirmed a buy rating and set a $213.00 target price (down from $225.00) on shares of Shire PLC in a report on Thursday, June 16th. Jefferies Group upped their target price on Shire PLC from $223.00 to $262.00 and gave the company a buy rating in a report on Friday, June 3rd. Finally, BTIG Research reaffirmed a buy rating and set a $230.00 target price on shares of Shire PLC in a report on Tuesday, July 12th. Five research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $230.67.
Shire PLC (NASDAQ:SHPG) opened at 199.57 on Wednesday. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The stock has a market cap of $59.44 billion, a PE ratio of 41.47 and a beta of 1.11. The stock has a 50 day moving average price of $196.34 and a 200-day moving average price of $185.44.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s revenue was up 55.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.63 earnings per share. On average, analysts expect that Shire PLC will post $12.93 EPS for the current year.
The business also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s payout ratio is presently 15.63%.
Several institutional investors have recently modified their holdings of SHPG. Renaissance Technologies LLC boosted its position in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock worth $53,841,000 after buying an additional 35,100 shares during the last quarter. Cullen Frost Bankers Inc. bought a new position in shares of Shire PLC during the second quarter worth about $17,387,000. Deltec Asset Management LLC boosted its position in shares of Shire PLC by 266.4% in the second quarter. Deltec Asset Management LLC now owns 32,975 shares of the biopharmaceutical company’s stock worth $6,070,000 after buying an additional 23,975 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of Shire PLC during the first quarter worth about $224,000. Finally, RNC Capital Management LLC bought a new position in shares of Shire PLC during the second quarter worth about $2,478,000. 24.26% of the stock is owned by institutional investors and hedge funds.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.